natgillin/translations-raw huggingface dataset:
b 95% confidence interval about the median progression free survival time. c Based on Cox proportional hazards model comparing the hazard functions associated with treatment groups, stratified by age (≤75 vs >75),diseases population (refractory to both Lenalidomide and Bortezomib vs not refractory to both drugs), and prior number of anti myeloma therapy (=2 vs >2). d The p-value is based on a stratified log-rank test with the same stratification factors as the above Cox model.
b 95% interval pouzdanosti za medijan razdoblja preživljenja bez progresije bolesti. c Na temelju Coxovog modela proporcionalnih hazarda kojim su se usporedile funkcije hazarda u terapijskim skupinama; stratificirano prema dobi (≤75 naspram >75), populacija s bolešću (refraktornom i na lenalidomid i na bortezomib naspram one koja nije refraktorna ni na jedan od ta dva lijeka) te prethodni broj antimijelomskih terapija (=2 naspram >2). d p-vrijednost temelji se na stratificiranom log rang testu s istim stratifikacijskim čimbenicima kao i u gornjem Coxovom modelu.
b 95% confidence interval about the median progression free survival time. c Based on Cox proportional hazards model comparing the hazard functions associated with treatment groups, stratified by age (≤75 vs >75),diseases population (refractory to both Lenalidomide and Bortezomib vs not refractory to both drugs), and prior number of anti myeloma therapy (=2 vs >2). d The p-value is based on a stratified log-rank test with the same stratification factors as the above Cox model.
b 95% interval pouzdanosti za medijan razdoblja ukupnog preživljenja. c Na temelju Coxovog modela proporcionalnih hazarda kojim su se usporedile funkcije hazarda u terapijskim skupinama; stratificirano prema dobi (≤75 naspram >75), populacija s bolešću (refraktornom i na lenalidomid i na bortezomib naspram one koja nije refraktorna ni na jedan od ta dva lijeka) te prethodni broj antimijelomskih terapija (=2 naspram >2). d p-vrijednost temelji se na nestratificiranom log rang testu s istim stratifikacijskim čimbenicima kao i u gornjem Coxovom modelu.
b a primary endpoint c Roche Cobas Amplicor PCR assay (LLOQ = 300 copies/ml)
b primarni ishod c Roche Cobas Amplicor PCR test (LLOQ = 300 kopija/ml)
b a primary endpoint. c Roche Cobas Amplicor PCR assay (LLOQ = 300 copies/ml)
b primarni ishod. c Roche Cobas Amplicor PCR test (LLOQ = 300 kopija/ml)
b Adjusted mean c P<0.05 for treatment difference
b Prilagođena srednja vrijednost c P<0,05 za razliku između liječenja
b ATV/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose 300 mg/200 mg tablets once daily). c LPV/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose 300 mg/200 mg tablets once daily). d Confidence interval.
b ATV/RTV s tenofovirdizoproksilfumaratom/emtricitabinom (fiksna doza 300 mg/200 mg, u tabletama, jedanput na dan). c LPV/RTV s tenofovirdizoproksilfumaratom/emtricitabinom (fiksna doza 300 mg/200 mg, u tabletama, jedanput na dan). d Interval pouzdanosti.
b ATV/RTV with tenofovir/emtricitabine (fixed dose 300 mg/200 mg tablets once daily). c LPV/RTV with tenofovir/emtricitabine (fixed dose 300 mg/200 mg tablets once daily). d Confidence interval.
b ATV/RTV s tenofovirom/emtricitabinom (fiksna doza 300 mg/200 mg, u tabletama, jedanput na dan). c LPV/RTV s tenofovirom/emtricitabinom (fiksna doza 300 mg/200 mg, u tabletama, jedanput na dan). d Interval pouzdanosti.
B cell counts returned to normal in these animals within 6 months of birth and did not compromise the reaction to immunization.
Broj B-stanica u tih se životinja vratio na normalnu razinu unutar 6 mjeseci od rođenja te nije ugrozio reakciju na cijepljenje.
B cell counts returned to normal levels in the offspring, and immunologic function was restored within 6 months of birth.
U mladunčadi se broj B stanica normalizirao, a imunološka funkcija ponovno je uspostavljena unutar 6 mjeseci nakon okota.
B cell function: All 12 subjects treated in the pivotal study were receiving IVIG therapy at the time of screening, and 7 subjects (58%) had discontinued IVIG use during 0-3 years follow-up after gene therapy.
Funkcija B stanica: Svih 12 ispitanika liječenih u pivotalnim ispitivanjima primalo je terapiju IVIG-om u trenutku probira, a 7 ispitanika (58%) prekinulo je primjenu IVIG-a tijekom razdoblja praćenja od 0 do 3 godine nakon genske terapije.
B cell levels in human neonates following maternal exposure to MabThera have not been studied in clinical trials.
Razine B-stanica u ljudske novorođenčadi nakon izloženosti majke lijeku MabThera nisu ispitivane u kliničkim ispitivanjima.
B cell numbers recovered after the cessation of belimumab treatment by about 1 year post-partum in adult monkeys and by 3 months of life in infant monkeys; IgM levels in infants exposed to belimumab in utero recovered by 6 months of age.
Broj B limfocita obnovio se nakon prestanka liječenja belimumabom nakon otprilike jedne godine poslije poroda u odraslih majmuna, te do 3. mjeseca života u novorođenčadi majmuna; razine IgM u novorođenčadi pri izloženosti belimumabu in utero oporavile su se do 6. mjeseca života.
b Disease Control Rate = SD+ ORR
b Stopa kontrole bolesti = SD+ ORR
b e.g. increased tendency to bruise, spontaneous haematoma, haemorrhagic diathesis c Identified in post-marketing experience d Frequencies derived from lab observations (Uric acid increases to >upper limit of normal from baseline below or within reference range.
b npr. povećana sklonost stvaranju modrica, spontanom hematomu, hemoragijskoj dijatezi c Identificirano nakon stavljanja lijeka u promet d Učestalosti dobivene iz laboratorijskih pretraga (razina uratne kiseline se povećava do >gornje granice normale u odnosu na početnu vrijednost koja je ispod ili unutar referentnog raspona.
B Frequencies of all uncommon adverse reactions were based on the individual mono-components data.
B Učestalost svih manje čestih nuspojava bazirala se na podacima za individualne monokomponentne.
b Frequency is based on laboratory values.
b Učestalost se temelji na laboratorijskim vrijednostima.
b Includes (very common) stomatitis, mouth ulceration, aphthous stomatitis and (uncommon) gingival pain, glossitis, lip ulceration, tongue ulceration c Includes (common) rash, rash erythematous, erythema and (uncommon) rash macular, rash maculo-papular, rash generalised d Frequency based upon number of women from 10 to 55 years of age while on treatment in the pooled data
b Uključuje (vrlo često) stomatitis, ulceracije u usnoj šupljini, aftozni stomatitis i (manje često) bol u zubnom mesu, glositis, ulceracije na usnicama, ulceracije na jeziku c Uključuje (često) osip, eritematozni osip, eritem i (manje često) makularni osip, makulopapularni osip, generalizirani osip d Učestalost temeljena na broju žena od 10 do 55 godina tijekom liječenja u objedinjenim podacima
B Infusion solution concentration is 0.77 mg/mL
B Koncentracija otopine za infuziju je 0,77 mg/ml.
b low-titer transient inhibitor formation
b stvaranje prolaznih inhibitora niskog titra
b LS Mean (SE). c Non-inferiority was tested using a pre-specified, fixed non-inferiority margin of 4% at Day 28 of Cycle 1. d Estimates were obtained from a Cox proportional hazards regression model. e P-value determined using a log-rank test.
b Srednja LS (SE). c Neinferiornost je provjerena pomoću prethodno specificirane fiksne granice neinferiornosti od 4% 28. dana ciklusa 1. d Procjene su dobivene pomoću Coxovog regresijskog modela proporcionalnog hazarda. e P-vrijednost određena je pomoću log-rang testa.
B LS mean and CI based on an ANCOVA model with baseline BCVA measurement as a covariate and a factor for treatment group.
B LS srednja vrijednost i CI temelje se na modelu ANCOVA s početnim mjerenjem BCVA kao kovarijata i čimbenikom u terapijskoj skupini.
b n = 292 c Analysis was based on subjects with nail psoriasis at baseline (81.8% of subjects).
Analiza je temeljena na bolesnicima s psorijazom noktiju na početku ispitivanja (81,8% bolesnika).
b n = 292. c Analysis was based on subjects with nail psoriasis at baseline (81.8% of subjects).
b n = 292 c Analiza je temeljena na bolesnicima s psorijazom noktiju na početku ispitivanja (81,8% bolesnika).
b n includes all patients who received at least one day of apheresis
b n uključuje sve bolesnike koji su imali barem jedan dan afereze
B n=128
B n=315c
B n=132 a
80d [74,85]
B n=187
41 (13)b
B n=193
146 (46)
B n=200 a
106b [86,128]
B n=202 a
B n=132a
B n=315c
CR CR+nCR
b p < 0.001 compared with etanercept
b p < 0,001 u usporedbi s etanerceptom
b p < 0.001 compared with etanercept c Patients with Itch NRS >= 4 at baseline: placebo N = 158, Taltz 80 mg Q4W N = 313, Taltz 80 mg Q2W N = 320, Etanercept N = 312
b p < 0,001 u usporedbi s etanerceptom c Bolesnici s početnim NRS rezultatom za svrbež od ≥ 4: placebo N = 158, Taltz 80 mg svaka 4 tjedna N = 313, Taltz 80 mg svaka 2 tjedna N = 320, etanercept N = 312
b p < 0.001, etanercept vs. placebo c p < 0.01, etanercept vs. placebo
b p < 0,001, etanercept u odnosu na placebo b p < 0,01, etanercept u odnosu na placebo
b p < 0.05 c nominally significant (p < 0.05)
b p < 0,05 c nominalno značajno (p < 0,05)
b p < 0.05. c Not applicable. d p < 0.001.
b p < 0,05. c Nije primjenjivo. d p < 0,001.
b p < 0.05. c Not applicable. d p < 0.001.
b p<0,05. c Nije primjenjivo. d p<0,001.
b p-value for time to deterioration based on stratified log-rank test c p-values were not adjusted for multiplicity
b p-vrijednost za vrijeme do pogoršanja temeljena na stratificiranom log-rank testu c p-vrijednosti nisu bile prilagođene za višestruke usporedbe
b p-value from the stratified log-rank test; analysis by line of therapy excludes stratification for therapeutic history; p < 0.0001 c Response population includes patients who had measurable disease at baseline and received at least 1 dose of study medicinal product. d p-value from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors; analysis by line of therapy excludes stratification for therapeutic history
b p-vrijednost iz stratificiranog log-rank testa; analiza po liniji liječenja isključuje stratifikaciju po prethodnim liječenjima; p < 0,0001 c Populacija s terapijskim odgovorom uključuje bolesnike koji su imali mjerljivu bolesti na početku liječenja i primili su najmanje 1 dozu ispitivanog lijeka. d p-vrijednost iz Cochran Mantel-Haenszelovog hi-kvadrat testa prilagođena za čimbenike stratifikacije; analiza po liniji terapije isključuje stratifikaciju po prethodnim liječenjima
b p-value=0.015
b p-vrijednost = 0,015
B p<0.001
B p<0,001
b p0.001 compared with placebo c A significant reduction in the incidence of hip fractures has not been demonstrated d p0.025 compared with placebo.
b p  0,001 u usporedbi s placebom c Nije dokazano značajno smanjenje incidencije prijeloma kuka d p  0,025 u usporedbi s placebom.
b Reported in  2 patients receiving KANUMA
b Zabilježeno u  2 bolesnika koji su primali KANUMU
b REYATAZ/RTV with tenofovir/emtricitabine (fixed dose 300 mg/200 mg tablets once daily).
b REYATAZ/RTV s tenofovirom/emtricitabinom (fiksna doza 300 mg/200 mg, u tableti, jedanput na dan).
b Subgroup analysis for patients on additional background of metformin (PPS-Completers, LOCF)
b Analiza podskupine u bolesnika na dodatnoj osnovnoj terapiji metforminom (bolesnici koji su završili ispitivanje po protokolu, LOCF)
B Turn the dose selector until the dose pointer lines up with your dose.
Okrećite izbornik doze dok se pokazivač doze ne poravna s Vašom dozom.
b Visually inspect the reconstituted solution for particulate matter or discoloration during reconstitution and prior to infusion.
Vizualno provjerite rekonstituiranu otopinu kako biste utvrdili da ne sadrži vidljive čestice ili da nije promijenila boju tijekom rekonstitucije i prije infuzije.
b Visually inspect the reconstituted solution for particulate matter or discolouration during reconstitution and prior to infusion.
Vizualno provjerite rekonstituiranu otopinu kako biste utvrdili da ne sadrži vidljive čestice ili da nije promijenila boju tijekom rekonstitucije i prije infuzije.
B) BCVA: Best Corrected Visual Acuity
B) BCVA (= Best corrected visual acuity): najbolje korigirana oštrina vida
B-1000 Brussels Belgium
B-1000 Brussels Belgija
B-1070 Brussels Belgium
B-1070 Bruxelles Belgija
B-1170 Brussels Belgique / Belgien
Terhulpsesteenweg 166 B-1170 Brussels Belgique / Belgien
B-1330 Rixensart Belgium
BE-1330 Rixensart Belgija
B-1420 Braine l'Alleud Belgium
B-1420 Braine l'Alleud Belgija
B-1420 Braine l’Alleud Belgium
B-1420 Braine l’Alleud Belgija
B-1420 Braine- l’Alleud Belgium
B-1420 Braine- l’Alleud Belgija
B-1420 Braine-L'Alleud Belgium
B-1420 Braine-L'Alleud Belgija
B-1420 Braine-l’Alleud Belgium
B-1420 Braine-l’Alleud Belgija
B-1800 Vilvoorde
Telecom Gardens, Medialaan 40 B-1800 Vilvoorde
B-1831 Diegem Belgium
B-1831 Diegem Belgija
B-2321 Hoogstraten Belgium
B-2321 Hoogstraten Belgija
B-2870 Puurs Belgium
B-2870 Puurs, Belgija
B-2870 Puurs Belgium
Češka Republika Belgija
B-2870 Puurs Belgium‌
B-2870 Puurs Belgija
B-2870 Puurs, Belgium.
B-2870 Puurs,
B-6900 Marche en Famenne Belgium
B-6900 Marche en Famenne Belgija
B-7860 Lessines Belgium
B-7860 Lessines Belgija
B-8020 Oostkamp Belgium
B-8020 Oostkamp Belgija
B-mode imaging of cardiac chambers, at rest or with stress: 2 ml.
Snimanje srčanih komora B-modom, pri mirovanju ili pri stres ehokardiografiji: 2 ml.
B. bronchiseptica cells 150 mg dl-α-tocopherol acetate
150 ml dl-α-tokoferol acetat
B. PACKAGE LEAFLET
B. UPUTA O LIJEKU
B. PACKAGE LEAFLET
B. UPUTA O VMP
B. PACKAGE LEAFLET
UPUTA O LIJEKU
B. PACKAGE LEAFLET
UPUTA O VMP
B. PACKAGE LEAFLET (PREFILLED SYRINGE)
B. UPUTA O LIJEKU (NAPUNJENA ŠTRCALJKA)
b.i.d. postpartum
b.i.d. postpartalno
B.PACKAGE LEAFLET
B.UPUTA O LIJEKU
B.PACKAGE LEAFLET
UPUTA O LIJEKU
B.V. contains lactose’)
B.V. sadrži laktozu”)
B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, MEDI 228030) 107.0±0.5 FFU***
B/Brisbane/60/2008 - poput kojeg je korišten soj (B/Brisbane/60/2008, MEDI 228030) 107,0±0,5 FFU
B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, wild type) .....................
B/Brisbane/60/2008 - sličan soj (B/Brisbane/60/2008, divlji tip) ......................
B/Malaysia/ 2506/2004
B/Malaysia/2506/ 2004
B/Massachusetts/2/2012-like strain (B/Massachusetts/2/2012, MEDI 237751) 107.0±0.5 FFU***
B/Massachusetts/2/2012 (B/Massachusetts/2/2012, MEDI 237751) 107,0±0,5 FFU
B/Massachusetts/2/2012-like strain (B/Massachusetts/2/2012, MEDI 237751) 107.0±0.5 FFU***
B/Massachusetts/2/2012 kao soj (B/Massachusetts/2/2012, MEDI 237751) 107,0±0,5 FFU
B/Phuket/3073/2013 - like strain (B/Phuket/3073/2013, MEDI 254977) 107.0±0.5 FFU***
B/Phuket/3073/2013 - poput kojeg je korišten soj (B/Phuket/3073/2013, MEDI 254977) 107,0±0,5 FFU
B/Phuket/3073/2013 - like strain (B/Phuket/3073/2013, MEDI 254977) 107.0±0.5 FFU***
B/Phuket/3073/2013 - poput kojeg je korišten soj (B/Phuket/3073/2013, MEDI 254977) 107.0±0.5 FFU
B/Phuket/3073/2013 – like strain (B/Utah/9/2014, wild type) 15 micrograms HA** per 0.5 ml dose
soj sličan B/Phuket/3073/2013 (divlji tip B/Utah/9/2014) 15 mikrograma HA** u dozi od 0,5 ml
B/Phuket/3073/2013 – like strain 15 micrograms HA** per 0.5 ml dose
soj sličan B/Phuket/3073/2013 15 mikrograma HA** u dozi od 0,5 ml
b: 2 morning, 3 evening
b: 2 ujutro, 3 navečer
b: n = number of responders/number of subjects with given genotype, and assigned treatment duration. c: Patients with genotype 3 low viral load (< 600,000 IU/mL) were to receive 24 weeks of treatment while those with genotype 3 and high viral load (≥ 600,000 IU/mL) were to receive 48 weeks of treatment.
b: n = broj ispitanika koji su odgovorili na liječenje/broj ispitanika s određenim genotipom i dodijeljenim trajanjem liječenja. c: Bolesnici s genotipom 3 i malim virusnim opterećenjem (< 600 000 IU/ml) liječeni su 24 tjedna, a bolesnici s genotipom 3 i velikim virusnim opterećenjem (≥ 600 000 IU/ml) 48 tjedana.
b: n = number of responders/number of subjects with given genotype, and assigned treatment duration. c: Patients with genotype 3 low viral load (< 600,000 IU/ml) were to receive 24 weeks of treatment while those with genotype 3 and high viral load (≥ 600,000 IU/ml) were to receive 48 weeks of treatment.
b: n = broj ispitanika koji su odgovorili na liječenje/broj ispitanika s određenim genotipom i dodijeljenim trajanjem liječenja. c: Bolesnici s genotipom 3 i malim virusnim opterećenjem (<600 000 IU/ml) liječeni su 24 tjedna, a bolesnici s genotipom 3 i velikim virusnim opterećenjem (≥600 000 IU/ml) liječeni su 48 tjedana.
B: observed in treatment of DVT, PE and prevention of recurrence as very common in women
B: uočeno kod liječenja DVT-a, plućne embolije i prevencije recidiva kao vrlo čestog kod žena
b: p = 0.002, Enbrel vs. placebo
b: p = 0,002, Enbrel u odnosu na placebo
B: PACKAGE LEAFLET
B. UPUTA O LIJEKU
B: To mix the recommended number of REYATAZ oral powder sachets with a beverage such as milk or water in a small drinking cup:
B: Za miješanje preporučenog broja vrećica REYATAZ oralnog praška s pićem kao što je mlijeko ili voda u maloj čaši:
B=bortezomib; Dx=dexamethasone; T=thalidomide
B=bortezomib; Dx=deksametazon; T=talidomid
Babies between nine and 12 months can be given the vaccine if they are considered to be at special risk, for example, if there is an outbreak in a day-care or the baby is travelling to an area where
Bebama u dobi između 9 i 12 mjeseci cjepivo se smije dati ako se smatra da su pod posebnim rizikom primjerice ako postoji epidemija u jaslicama ili dijete putuje u područja u kojima su morbili česti.
Baby
Djeca
Back
ILI
back and abdominal pain, pain
bol u trbuhu i bol u leđima, bol
back and abdominal pain, pain
bolovi u trbuhu i bol u leđima, bol
Back of thigh, or in the back of your arm.
Stražnji dio nadlaktice.
back or limb pain, muscle pain, joint pain, muscle and bone discomfort, swelling of the extremities or joints feeling cold or hot, flu-like symptoms, feeling sick, feeling lack of energy
bol u leđima ili udovima, bol u mišićima, bol u zglobovima, nelagoda u mišićima i kostima, oticanje udova ili zglobova osjećaj hladnoće ili vrućine, simptomi nalik gripi, mučnina, nedostatak energije
Back or muscle pain, increase in blood of a muscle enzyme (creatine phosphokinase), muscle stiffness
bolovi u leđima ili mišićima, povećanje jednog mišićnog enzima u krvi (kreatin fosfokinaza), ukočenost mišića
Back or muscle pain; increase in blood of a muscle enzyme (creatine phosphokinase), muscle stiffness
bolovi u leđima ili mišićima, povećanje jednog mišićnog enzima u krvi (kreatin fosfokinaza), ukočenost mišića
back pain
bol u abdomenu, mučnina
Back pain
Bol u leñima
Back pain
bol u leĎima
back pain
bol u leđima
Back pain
bol u leđima,
back pain
bolovi u leđima
Back pain
bolovi u leđima,
back pain
križobolja
Back pain
promjene na noktima
Back pain
u mišićima i
Back pain (12.8%) (G3/4: 1.5%)
Bol u leđima (12,8%) (G3/4: 1,5%)
back pain (23%), upper respiratory tract infection (20%), anaemia (27%), neutropenia (22%) and thrombocytopenia (20%).
u leđima (23%), infekcija gornjih dišnih putova (20%), anemija (27%), neutropenija (22%) i trombocitopenija (20%).
Back pain (e.g. sciatica), muscle spasms, myalgia
Bol u leđima (npr. išijas), grčevi mišića, mialgija,
Back pain (e.g. sciatica), muscle spasms, myalgia,
Bol u leđima (npr. išijas), grčevi mišića, mijalgija,
Back pain Arthralgia
Bol u leđima Artralgija Bol u ektremitetima
back pain blood in your urine.
bol u leđima krv u mokraći.
back pain feeling of weakness or tiredness, feeling unwell.
bol u leđima osjećaj slabosti ili umora, općenito loše osjećanje.
back pain generally feeling unwell
bol u leđima opće loše stanje
Back pain Increase in creatine phosphokinase Myalgia Increased muscle tone and cramping
bolovi u leđima, povišena kreatin fosfokinaza, mialgija, pojačan tonus mišića i grčevi
back pain low blood pressure.
bol u leđima nizak krvni tlak.
back pain low calcium levels in the blood (hypocalcaemia).
bol u leđima niske razine kalcija u krvi (hipokalcemija)
Back pain Muscle tightness
bol u leđima ukočenost mišića
back pain or joint pain
bol u leđima ili zglobovima
back pain weakness/loss of strength/tiredness
bol u leđima slabost/gubitak snage/umor
back pain*
bol u leđima
Back pain*
bolovi u leđima
Back pain*, pain in extremity*, muscle spasms, muscular weakness, neck pain
bol u leđima*, bol u udovima*, grčevi u mišićima, slabost mišića, bol u vratu
back pain,
bol u leđima,
Back pain,
u leđima, bol u
Back pain, aching muscles and joints
Bol u leđima, bol u mišićima i zglobovima
Back pain, arthralgia, myalgia, muscle cramp
Bol u leđima, artralgija, mijalgija, grčevi u mišićima
Back pain, arthralgia, pain in extremity, myalgia, muscle spasms, muscular weakness
bol u leđima, artralgija, bol u ekstremitetima, mialgija, spazam mišića, slabost mišića
Back pain, arthritis, muscle weakness, bone pain, neck pain, musculoskelet al pain, muscle cramps
bol u leđima, artritis, slabost mišića, bolovi u kostima, bol u vratu, bol u mišićima i kostima, grčevi u mišićima
back pain, bone pain, pain in arms and legs
bol u leđima, bol u kostima, bol u rukama i nogama
back pain, chest pain,
bol u leđima, bol u prsištu,
Back pain, Groin pain
bol u leđima, preponska bol
Back pain, joint pain.
Bol u leđima, bol u zglobovima.
Back pain, joint swelling, muscle spasm,
Bol u leđima, oticanje zglobova, spazmi mišića, bol u ekstremitetima, plantarni fasciitis
back pain, muscle spasms
bol u leđima, mišićni grčevi
Back pain, musculoskeletal chest pain, pain in extremity, bone pain
bol u leđima, mišićno-koštana bol u prsištu, bol u ekstremitetu, bol u kostima
Back pain, myalgia
Bolovi u leđima, mialgija
Back pain, myalgia
križobolja, mialgija
Back pain, myalgia, arthralgia.
Bol u leđima, mialgija, artralgija
Back pain, Myalgia, Pain in extremity
bol u leđima, mialgija, bol u ekstremitetima
Back pain, pain in an arm or leg, bone pain, muscle pain, muscle weakness
Bolovi u leđima, bolovi u rukama i nogama, bolovi u kostima, bolovi u mišićima, slabost mišića
back pain, pain in arms or legs
bol u leđima, bol u rukama ili nogama
back pain, pain in extremities such as fingers and toes
udovima kao što su prsti na nogama i rukama
Back pain, pain in extremity
bol u leđima, bol u udovima
back pain, pain in extremity (leg pain)
bol u leđima, bol u udovima (bol u nogama)
back pain, pain in extremity, bone pain, muscular weakness, myalgia
bol u leđima, bol u udovima, bol u kostima, slabost mišića, mialgija
back pain, pain in extremity, painful swollen joints, bone pain
bolovi u leđima, bolovi u udovima, bolni i natečeni zglobovi, bolovi u kostima
back pain, pain in the muscles.
bol u leđima, bol u mišićima;
Back pain.
Bol u leđima.
back pain;
bol u leđima;
back pain; pain in bone/muscle; muscle tenderness or weakness; neck pain; pain in arms or legs; inflammation of the tendons; decrease in the amount of minerals in the bone
bol u leđima; bol u kostima/mišićima; osjetljivost ili slabost mišića; bol u vratu; bol u rukama ili nogama; upala tetiva; smanjenje količine minerala u kostima
BACK TO PACKAGE
VRAĆANJE U KUTIJU
Back, muscle or joint pain
bol u leđima, mišićima ili zglobovima
Back, neck and flank pain
bol u leđima, vratu i boku
Back, neck or jaw pain, pain in extremity, musculoskeletal discomfort
bol u leđima, vratu i čeljusti, bol u ekstremitetima, nelagoda u kostima i mišićima
Back, pubic or groin pain Ligament disorder Ligament pain Musculoskeletal discomfort
bol u leđima, pubičnoj regiji ili preponama poremećaj ligamenata bol u ligamentima mišićno-koštana nelagoda
Back- Neulasta reference guide:
Stražnja strana - Vodič za primjenu lijeka Neulasta:
Back- Prolia reference guide:
Stražnja strana - Vodič za primjenu lijeka Prolia:
Back-up contraception is not needed.
Dodatna kontracepcija nije potrebna.
Background counta
Pozadinski broja
Background information on mycophenolate mofetil teratogenicity and mutagenicity in humans.
Pozadinske informacije o teratogenosti i mutagenosti mofetilmikofenolata u ljudi.